drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy
drug_description
Autologous T cells genetically engineered to express chimeric antigen receptors targeting CD19, CD20, and BCMA; upon antigen binding, CAR signaling (CD3ΞΆ with costimulatory domains) activates T-cell proliferation, cytokine release, and cytotoxic killing of malignant B-lineage and plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors recognizing CD19, CD20, and BCMA; antigen binding activates CD3zeta and costimulatory signaling, inducing T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant B-lineage cells and plasma cells, with multi-antigen targeting to limit antigen escape.
drug_name
CD19/CD20/BCMA CAR-T cells
nct_id_drug_ref
NCT06732232